Rapid quantitative assay to measure CFTR function in a primary intestinal culture model
The invention relates to an assay for diagnosing a disease or affliction that affects fluid uptake or secretion or for studying the effectiveness of one or more drugs for treating the disease or affliction, wherein the assay comprises measuring swelling of one or more organoids.
1. An in vitro method for diagnosing cystic fibrosis, wherein the method comprises
stimulation of one or more organoids, generated from primary cells derived from a patient, with a cystic fibrosis transmembrane receptor (CFTR) activator,
measuring swelling of one or more organoids generated from primary cells,
wherein swelling means an increase in size of the one or more organoids due to fluid uptake, and
wherein the swelling is CFTR dependent, and
wherein a smaller size of said one or more organoids compared to a control organoid indicates the presence of cystic fibrosis.
2. An in vitro method for identifying a drug candidate for treating cystic fibrosis, wherein the method comprises
stimulation of one or more cystic fibrosis organoids generated from primary cells derived from a patient of interest with a cystic fibrosis transmembrane receptor (CFTR) activator;
stimulation of the one or more organoids with a drug known to affect CFTR function or with a drug being tested for its efficacy in affecting CFTR function; and
measuring swelling of the one or more organoids, wherein swelling means an increase in size of the one or more organoids due to fluid uptake, and wherein the swelling is CFTR-dependent, and optionally comparing the swelling of the organoid to the swelling of an organoid which has been stimulated with the CFTR activator but has not been stimulated with the drug;
wherein an increase in swelling of the one or more organoids in response to stimulation by a drug indicates that the patient is responsive to treatment with the drug.
3. An in vitro method for identifying a drug candidate for treating cystic fibrosis, wherein the method comprises
stimulation of one or more organoids generated from primary cells with a CFTR activator;
stimulation of the one or more organoids with a drug known to affect CFTR function or with a drug being tested for its efficacy in affecting CFTR function; and
measuring swelling of the one or more organoids, wherein swelling means an increase in size of the one or more organoids due to fluid uptake, and wherein the swelling is CFTR-dependent, and optionally comparing the swelling of the organoid to the swelling of an organoid which has been stimulated with the CFTR activator but has not been stimulated with the drug;
wherein swelling of the one or more organoids in response to stimulation by the drug indicates that the drug is effective for treatment of functional restoration of mutant CFTR.
4. The method according to any one of claims 1 , 2 , and 3 , wherein the organoids are generated from primary human cells.
5. The method according to any one of claims 1 , 2 , and 3 , wherein the organoids are epithelial organoids.
6. The method according to claim 2 or claim 3 , wherein the increase in size is determined by comparison to a healthy control organoid.
7. The method according to any one of claims 1 , 2 , and 3 , wherein the CFTR activator is forskolin.
8. The method according to any one of claims 1 , 2 , and 3 , wherein the one or more organoids are intestinal or lung organoids.
9. The method according to claim 8 , wherein the one or more organoids are intestinal organoids, and the method further comprises generating the one or more intestinal organoids by expanding intestinal stem cells into closed organoids which include a closed lumen on the apical membrane of the cells.
10. The method of claim 2 or claim 3 , wherein the one or more drugs are a library of potential drugs.